Evidence map›Paper›PMID 30529266›Full record

ArticleCellular signalling2019

Cleavage of arrestin-3 by caspases attenuates cell death by precluding arrestin-dependent JNK activation.

Seunghyi Kook, Sergey A Vishnivetskiy, Vsevolod V Gurevich, Eugenia V Gurevich

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Arrestins as Possible Drug Targets.Biomolecules & therapeutics · 2025
    Review
  2. Article
  3. GPCR-dependent and -independent arrestin signaling.Trends in pharmacological sciences · 2024
    Review
  4. Arrestins: A Small Family of Multi-Functional Proteins.International journal of molecular sciences · 2024
    Review
  5. Pharmacological reviews · 2023
    Review
  6. Roles of Nitric Oxide in Brain Ischemia and Reperfusion.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Targeting arrestin interactions with its partners for therapeutic purposes.Advances in protein chemistry and structural biology · 2020
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Seunghyi KookDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States.
Sergey A VishnivetskiyDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States.
Vsevolod V GurevichDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States.
Eugenia V GurevichDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States. Electronic address: Eugenia.Gurevich@vanderbilt.edu.
Vanderbilt University Medical Center · US

Funding

STRUCTURE/FUNCTION STUDIES OF VISUAL ARRESTINR01EY011500 · NEI · VANDERBILT UNIVERSITY · PI T M Iverson · 1997 to 2026
$12.3M
Targeted Engineering of Designer Arrestins to Regulate Cell SignalingR35GM122491 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2017 to 2021
$2.6M
Arrestin interactions with non-receptor binding partnersR01GM077561 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2007 to 2015
$2.3M
Signaling regulation in the striatum in Parkinson's diseaseR01NS065868 · NINDS · VANDERBILT UNIVERSITY · PI GUREVICH, EUGENIA V · 2009 to 2013
$1.7M
Dopamine Receptor Trafficking in Parkinson's DiseaseR01NS045117 · NINDS · VANDERBILT UNIVERSITY · PI GUREVICH, EUGENIA V · 2003 to 2007
$1.6M
Regulation of GPCR signaling with receptor-specific arrestinsR01GM109955 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2015 to 2017
$1.1M
Molecular mechanisms of arrestin functionR01GM063097 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2001 to 2004
$982k
NEI NIH HHS R01 EY011500NIGMS NIH HHS R01 GM063097NIGMS NIH HHS R01 GM077561NIGMS NIH HHS R01 GM109955NIGMS NIH HHS R35 GM122491NINDS NIH HHS R01 NS045117NINDS NIH HHS R01 NS065868
6 · The paper itself

Abstract

The two non-visual subtypes, arrestin-2 and arrestin-3, are ubiquitously expressed and bind hundreds of G protein-coupled receptors. In addition, these arrestins also interact with dozens of non-receptor signaling proteins, including c-Src, ERK and JNK, that regulate cell death and survival. Arrestin-3 facilitates the activation of JNK family kinases, which are important players in the regulation of apoptosis. Here we show that arrestin-3 is specifically cleaved at Asp366, Asp405 and Asp406 by caspases during the apoptotic cell death. This results in the generation of one main cleavage product, arrestin-3-(1-366). The formation of this fragment occurs in a dose-dependent manner with the increase of fraction of apoptotic cells upon etoposide treatment. In contrast to a caspase-resistant mutant (D366/405/406E) the arrestin-3-(1-366) fragment reduces the apoptosis of etoposide-treated cells. We found that caspase cleavage did not affect the binding of the arrestin-3 to JNK3, but prevented facilitation of its activation, in contrast to the caspase-resistant mutant, which facilitated JNK activation similar to WT arrestin-3, likely due to decreased binding of the upstream kinases ASK1 and MKK4/7. The data suggest that caspase-generated arrestin-3-(1-366) prevents the signaling in the ASK1-MKK4/7-JNK1/2/3 cascade and protects cells, thereby suppressing apoptosis.

Indexed as

AnimalsApoptosisArrestinsCaspasesChlorocebus aethiopsCOS CellsEtoposideMAP Kinase Kinase 4MAP Kinase Kinase Kinase 5arrestin3ArrestinsCaspasesEtoposideMAP Kinase Kinase 4MAP Kinase Kinase Kinase 5Arrestin-3Caspase cleavageCell death: apoptosisJNKMAP kinases

Identifiers

PMID30529266
PMCPMC6321783
OpenAlexW2902906086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.